357 related articles for article (PubMed ID: 34951921)
21. Emerging Immunomodulatory Therapies and New Treatment Paradigms for Axial Spondyloarthritis.
Mease P
Curr Rheumatol Rep; 2019 Jun; 21(7):35. PubMed ID: 31172311
[TBL] [Abstract][Full Text] [Related]
22. Developments in therapies for spondyloarthritis.
Sieper J
Nat Rev Rheumatol; 2012 Apr; 8(5):280-7. PubMed ID: 22487798
[TBL] [Abstract][Full Text] [Related]
23. Clinical efficacy of JAK inhibitors on enthesitis in spondyloarthropathy: A scoping literature review.
Jubber A; Tahir H; Moorthy A
Musculoskeletal Care; 2023 Dec; 21(4):1195-1203. PubMed ID: 37501580
[TBL] [Abstract][Full Text] [Related]
24. The term 'non-radiographic axial spondyloarthritis' is much more important to classify than to diagnose patients with axial spondyloarthritis.
Deodhar A; Strand V; Kay J; Braun J
Ann Rheum Dis; 2016 May; 75(5):791-4. PubMed ID: 26768406
[TBL] [Abstract][Full Text] [Related]
25. Biologics for treating axial spondyloarthritis.
Jones A; Ciurtin C; Ismajli M; Leandro M; Sengupta R; Machado PM
Expert Opin Biol Ther; 2018 Jun; 18(6):641-652. PubMed ID: 29681195
[TBL] [Abstract][Full Text] [Related]
26. Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi.
Malaviya AN; Kalyani A; Rawat R; Gogia SB
Int J Rheum Dis; 2015 Sep; 18(7):736-41. PubMed ID: 26172961
[TBL] [Abstract][Full Text] [Related]
27. IL-17 inhibition in axial spondyloarthritis: current and future perspectives.
Torgutalp M; Poddubnyy D
Expert Opin Biol Ther; 2019 Jul; 19(7):631-641. PubMed ID: 30957574
[TBL] [Abstract][Full Text] [Related]
28. Ixekizumab for treating ankylosing spondylitis.
Kiwalkar S; Beier S; Deodhar A
Immunotherapy; 2019 Oct; 11(15):1273-1282. PubMed ID: 31530049
[TBL] [Abstract][Full Text] [Related]
29. No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?
Braun J; Landewé RB
Ann Rheum Dis; 2022 Apr; 81(4):466-468. PubMed ID: 34656991
[TBL] [Abstract][Full Text] [Related]
30. Beyond the TNF-α Inhibitors: New and Emerging Targeted Therapies for Patients with Axial Spondyloarthritis and their Relation to Pathophysiology.
Pedersen SJ; Maksymowych WP
Drugs; 2018 Sep; 78(14):1397-1418. PubMed ID: 30171593
[TBL] [Abstract][Full Text] [Related]
31. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
[TBL] [Abstract][Full Text] [Related]
32. New targeted therapies in spondyloarthritis: what are the limits?
Wendling D
Immunotherapy; 2019 May; 11(7):557-560. PubMed ID: 30943857
[No Abstract] [Full Text] [Related]
33. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
Callhoff J; Sieper J; Weiß A; Zink A; Listing J
Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
[TBL] [Abstract][Full Text] [Related]
34. The Effect of TNF Inhibition on Bone Density and Fracture Risk and of IL17 Inhibition on Radiographic Progression and Bone Density in Patients with Axial Spondyloarthritis: a Systematic Literature Review.
Ashany D; Stein EM; Goto R; Goodman SM
Curr Rheumatol Rep; 2019 Mar; 21(5):20. PubMed ID: 30868279
[TBL] [Abstract][Full Text] [Related]
35. The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond.
Dubash S; Bridgewood C; McGonagle D; Marzo-Ortega H
Expert Rev Clin Immunol; 2019 Feb; 15(2):123-134. PubMed ID: 30576610
[TBL] [Abstract][Full Text] [Related]
36. The role of secukinumab in the treatment of ankylosing spondylitis.
Shah R; Perry L; Deodhar A
Immunotherapy; 2015; 7(12):1241-7. PubMed ID: 26595091
[TBL] [Abstract][Full Text] [Related]
37. Tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis-time to reconsider treatment guidelines? A case series and review of literature.
Rocha FAC; Pinto ACMD; Lopes JR; Deodhar A
Clin Rheumatol; 2021 May; 40(5):1881-1887. PubMed ID: 33230684
[TBL] [Abstract][Full Text] [Related]
38. Structural disease modification in axial spondyloarthritis.
Dinneen B; O'Shea F; Gensler L
Best Pract Res Clin Rheumatol; 2023 Sep; 37(3):101898. PubMed ID: 38042689
[TBL] [Abstract][Full Text] [Related]
39. Ixekizumab: an IL-17A inhibitor for the treatment of axial Spondylarthritis.
Harrison SR; Marzo-Ortega H
Expert Rev Clin Immunol; 2021 Oct; 17(10):1059-1071. PubMed ID: 34407705
[TBL] [Abstract][Full Text] [Related]
40. Treatment strategies in axial spondyloarthritis: what, when and how?
Fragoulis GE; Siebert S
Rheumatology (Oxford); 2020 Oct; 59(Suppl4):iv79-iv89. PubMed ID: 33053192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
